Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis

Clinic of Endocrinology and Metabolic Disorders, Macedonia700 enrolled

Overview

This observational study assess the safety of intravenous Ibandronate (Bonviva) intermittent administration in patients with postmenopausal osteoporosis and the efficacy of IV Ibandronate (Bonviva treatment through relative lumbar spine and hip bone mineral densitometry form baseline at year 1)

Study Type

OBSERVATIONAL

Enrollment

700

Conditions

Osteoporosis

Interventions

Ibandronic acidDRUG

As prescribed by physician

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients had post menopausal osteoporosis * Patients had no contraindication for bisphosphonates * Patients had been naive for ibandronate therapy * Patients who have signed informed consent and are willing to share their data for data analysis Exclusion Criteria: * Is not Ibandronate naïve * Hypersensitivity to any component of the bisphosphonates Ibandronate; * Administration of any investigational drug within 30 days preceding the first dose of the study drug.

Outcomes

Primary Outcomes

Number of Participants with Adverse Events and Serious Adverse Events as a Measure of Safety and Tolerability of intravenous Ibandronate intermittent administration in patients with postmenopausal osteoporosis

Time frame: end of observation 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.